{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:39Z","timestamp":1775488119862,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Henan Provincial Medical Science and Technology Research Program","award":["NO.LHGJ20240293"],"award-info":[{"award-number":["NO.LHGJ20240293"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:p>\n                    Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (\u03c7\n                    <jats:sup>2<\/jats:sup>\n                    ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI\u2005&gt;1, proportional reporting ratio\u2005\u22652 with \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005\u22654, or Bayesian confidence propagation neural network information component (IC)-2SD\u2005&gt;0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for \u201cprostatic specific antigen increased\u201d (Leuprolide: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u200584,009.65, IC-2SD\u2005=\u20055.42; Goserelin: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u2005820.31, IC-2SD\u2005=\u20053.38), \u201cblood testosterone increased\u201d (Leuprolide: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u200522,845.52, IC-2SD\u2005=\u20055.56; Goserelin: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u2005290.23, IC-2SD\u2005=\u20052.28), and \u201cprostatic specific antigen abnormal\u201d (Leuprolide: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u200551,615.98, IC-2SD\u2005=\u20056.46; Goserelin: \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    \u2005=\u2005422.43, IC-2SD\u2005=\u20052.16). Additional strong signals, such as \u201cprostate cancer metastatic\u201d and \u201chot flush,\u201d were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in \u201cReproductive system and breast disorders,\u201d \u201cNeoplastic benign and malignant conditions,\u201d and procedure-related categories, whereas Goserelin was more strongly linked to \u201cEndocrine disorders.\u201d These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048207","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:01:01Z","timestamp":1775232061000},"page":"e48207","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines"],"prefix":"10.1097","volume":"105","author":[{"given":"Fangyu","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1182-1157","authenticated-orcid":false,"given":"Ningning","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41419-022-05185-x","article-title":"Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.","volume":"13","author":"Shen","year":"2022","journal-title":"Cell Death Dis"},{"key":"R4-20260406","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R5-20260406","first-page":"483","article-title":"Historical redlining and clustering of present-day breast cancer factors.","volume":"36","author":"Lima","year":"2025","journal-title":"Cancer Causes Control"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"dyae165","DOI":"10.1093\/ije\/dyae165","article-title":"Associations between breastfeeding and breast cancer risk through mammographic breast density in a cohort of Korean women.","volume":"54","author":"Kim","year":"2024","journal-title":"Int J Epidemiol"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/phn.13504","article-title":"Modifiable risk factors for breast cancer: insights from systematic reviews.","volume":"42","author":"Li","year":"2025","journal-title":"Public Health Nurs"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13058-024-01922-6","article-title":"Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.","volume":"26","author":"Kresovich","year":"2024","journal-title":"Breast Cancer Res"},{"key":"R9-20260406","first-page":"524","article-title":"Breast cancer statistics, 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jnci\/djae172","article-title":"Risk factors for breast cancer subtypes by race and ethnicity: a scoping review.","volume":"116","author":"Hurson","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"900","DOI":"10.6004\/jnccn.2023.0046","article-title":"NCCN Guidelines\u00ae insights: breast cancer screening and diagnosis, Version 1.2023.","volume":"21","author":"Bevers","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer.","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13058-024-01903-9","article-title":"Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.","volume":"26","author":"Lee","year":"2024","journal-title":"Breast Cancer Res"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, Version 3.2024.","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1471-0528.14838","article-title":"Diagnosis and management of endometriosis: a systematic review of international and national guidelines.","volume":"125","author":"Hirsch","year":"2018","journal-title":"BJOG"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmig.2024.11.006","article-title":"Use of uterine artery embolization for the treatment of uterine fibroids: a comparative review of major national guidelines.","volume":"32","author":"Cottrell","year":"2025","journal-title":"J Minim Invasive Gynecol"},{"key":"R19-20260406","first-page":"1412","article-title":"Guidelines on assisted reproduction.","volume":"298","author":"Delamothe","year":"1989","journal-title":"BMJ"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-024-07323-9","article-title":"Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.","volume":"206","author":"Chen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-023-06877-4","article-title":"Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.","volume":"198","author":"Kim","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-021-06368-4","article-title":"Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.","volume":"190","author":"Sukumar","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database.","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/curroncol31080314","article-title":"An overview of long-acting GnRH agonists in premenopausal breast cancer patients: survivorship challenges and management.","volume":"31","author":"LeVasseur","year":"2024","journal-title":"Curr Oncol"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer.","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:37Z","timestamp":1775484097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048207","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}